AmBase Corporation acts as investment banker/financial advisor toSDG, Inc. and all of its subsidiaries and affiliates. SDG, Inc. is a development stage company that specializes in reating new technology-specific companies that are dedicated to the clinical and commercial development of proprietary, targeted liposomal delivery systems for pharmaceutical therapies and consumer product ingredients.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-6.62M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -1742.45% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.10 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.10 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.07 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 84.94M |
| Free Float | 24.21M |
| Market Capitalization | $27.35M |
| Average Volume (Last 20 Days) | 0.01M |
| Beta (Past 60 Months) | 0.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 71.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |